We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A Biologics License Application (BLA) for the anti-PD-L1 antibody: envafolimab injection co-developed by Alphamab, 3D Medicines, and Simcere has been formally filed to the National Medical Products Administration of China (NMPA) on Nov. 16.